KPC (Hengqin, Zhuhai) Technology

KPC (Hengqin) Technology is a strategic subsidiary of Kunming Pharmaceutical Group (KPC), located in the Hengqin New Area of Zhuhai, China. The company serves as a primary hub for KPC's international business expansion, focusing on the global registration, research, and development of innovative pharmaceuticals. Its parent company is a world-renowned leader in the production of artemisinin-based anti-malarial drugs and specialized cardiovascular treatments derived from Panax notoginseng. KPC (Hengqin) leverages its location to facilitate cross-border collaborations and clinical trials, aiming to modernize traditional botanical medicines for international markets. The entity plays a critical role in advancing KPC's pipeline, which includes treatments for chronic diseases such as systemic lupus erythematosus and osteoporosis.